SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001662774-24-000013
Filing Date
2024-11-14
Accepted
2024-11-14 06:55:48
Documents
13
Period of Report
2024-11-12
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K qncx-20241112.htm   iXBRL 8-K 25634
  Complete submission text file 0001662774-24-000013.txt   151794

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT qncx-20241112.xsd EX-101.SCH 1785
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT qncx-20241112_lab.xml EX-101.LAB 22534
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT qncx-20241112_pre.xml EX-101.PRE 13048
15 EXTRACTED XBRL INSTANCE DOCUMENT qncx-20241112_htm.xml XML 2836
Mailing Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080 415-910-5717
Quince Therapeutics, Inc. (Filer) CIK: 0001662774 (see all company filings)

IRS No.: 901024039 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38890 | Film No.: 241457034
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)